Israeli medical cannabis company CannAssureannounced they will be developing a topical cannabis spray to treat a variety of inflammatory skin conditions, along with Swedish Pharmaceutical company Lipidor AB, which specializes in dermatology.
The companies signed a development agreement together after successfully completing the feasibility stage in the process of developing an over-the-counter (OTC) topical spray for the treatment of inflammatory skin conditions such as atopic dermatitis, psoriasis, pain and lesions.
In addition to the development deal, Cannassure will now have the exclusive right to use Lipidor’s innovative AKVANO® topical spray technology.
According to Cannassure’s estimates, the combined treatment market for all of these chronic illnesses and symptoms could be worth over $50 billion by 2027.
Cannassure said that it has proven that the cannabinoids can be well combined into the AKVANO system, into a homogeneous, uniform and stable formulation.
Cannassure CEO Ran Amir stated that the company looked forward to the joint development process, saying that “The AKVANO non-touch application paired with an excellent uptake of active substance in different skin layers opens up the door for new high-potential treatments with great patient benefits.”
After the OTC topical spray, Amir said that Cannassure plans to expand to also developing prescription-based pharmaceutical products, adding that they have seen “significant interest from distributors.”